Literature DB >> 31768396

GLP-2 Analogues as First Specific Treatment of Intestinal Failure.

Irina Blumenstein1.   

Abstract

Growth factors and other trophic hormones play an important role in the specific treatment of intestinal failure, with teduglutide being the first approved medication specifically for use in patients with intestinal failure in conjunction with specialized nutritional support. This article focusses on the mode of action, the pivotal study data, treatment response prediction as well as new substances in phase clinical trials.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Growth factors; Intestinal failure; Mode of action; New substances in phase clinical trials; Pivotal study data; Specific treatment; Teduglutide; Treatment response prediction; Trophic hormones

Year:  2019        PMID： 31768396      PMCID： PMC6873062          DOI： 10.1159/000503043

Source DB:  PubMed          Journal:  Visc Med        ISSN： 2297-4725


  14 in total

Review 1.  AGA technical review on short bowel syndrome and intestinal transplantation.

Authors:  Alan L Buchman; James Scolapio; Jon Fryer
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

2.  Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.

Authors:  P B Jeppesen; E L Sanguinetti; A Buchman; L Howard; J S Scolapio; T R Ziegler; J Gregory; K A Tappenden; J Holst; P B Mortensen
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 3.  Growth factors: possible roles for clinical management of the short bowel syndrome.

Authors:  Mark E McMellen; Derek Wakeman; Shannon W Longshore; Lucas A McDuffie; Brad W Warner
Journal:  Semin Pediatr Surg       Date:  2010-02       Impact factor: 2.754

4.  Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.

Authors:  Stephen J D O'Keefe; Palle B Jeppesen; Richard Gilroy; Marek Pertkiewicz; Johane P Allard; Bernard Messing
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

5.  The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport.

Authors:  C I Cheeseman; R Tsang
Journal:  Am J Physiol       Date:  1996-09

6.  Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.

Authors:  Palle B Jeppesen; Marek Pertkiewicz; Bernard Messing; Kishore Iyer; Douglas L Seidner; Stephen J D O'keefe; Alastair Forbes; Hartmut Heinze; Bo Joelsson
Journal:  Gastroenterology       Date:  2012-09-11       Impact factor: 22.682

Review 7.  Short bowel syndrome: recent clinical outcomes with growth hormone.

Authors:  James S Scolapio
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

8.  Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.

Authors:  P B Jeppesen; R Gilroy; M Pertkiewicz; J P Allard; B Messing; S J O'Keefe
Journal:  Gut       Date:  2011-02-11       Impact factor: 23.059

9.  Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome.

Authors:  Lauren K Schwartz; Stephen J D O'Keefe; Ken Fujioka; Simon M Gabe; Georg Lamprecht; Ulrich-Frank Pape; Benjamin Li; Nader N Youssef; Palle B Jeppesen
Journal:  Clin Transl Gastroenterol       Date:  2016-02-04       Impact factor: 4.488

10.  GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting.

Authors:  Marc Schoeler; Thomas Klag; Judith Wendler; Simon Bernhard; Michael Adolph; Andreas Kirschniak; Martin Goetz; Nisar Malek; Jan Wehkamp
Journal:  Therap Adv Gastroenterol       Date:  2018-08-30       Impact factor: 4.409
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.